Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.71 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.71 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.49 |
| ▸ | ERN1 | O75460 | 8/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707253 | 0.84 | CRHBP (1.00) | CRHBPCRHR2ABCC1ERN1ABCB1 | |
| SCHEMBL14283133 | 0.81 | ABCB1 (0.58) | CRHBPCRHR2ABCC1ABCB1KCNMA1 | |
| SCHEMBL25302339 | 0.81 | ABCB1 (0.52) | CRHBPCRHR2ABCC1ABCB1KCNMA1 | |
| SCHEMBL27769307 | 0.77 | TSHR (0.59) | CRHBPCRHR2ABCC1ABCB1KCNMA1 | |
| SCHEMBL4132017 | 0.76 | GPR35 (0.69) | KCNMA1 | |
| SCHEMBL31392530 | 0.76 | GPR35 (0.69) | KCNMA1 | |
| SCHEMBL23402067 | 0.76 | PTPN1 (0.50) | CRHBPCRHR2PTPN1AKR1C2AKR1C1 | |
| SCHEMBL11067720 | 0.76 | GPR35 (0.61) | — | |
| SCHEMBL3317242 | 0.76 | CRHBP (0.77) | CRHBPCRHR2ABCC1ERN1PTPN1 | |
| SCHEMBL27707704 | 0.75 | MAPT (0.60) | CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | LIGAND PHARMACEUTICALS INC | 2004-03-11 | — | — | US | disclosed |
| US-6593493-B1 | 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes | LIGAND PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1216221-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019770-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | RXRB, RXRG, RXRA | CRHBP 329/4885CRHR2 334/4885ABCC1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.